This Global website is not intended to represent or suggest that particular products are approved or authorized in any particular jurisdiction. You should not construe anything on this website as a promotion or solicitation for any product or service, or as suggesting that a product or service be used where it is not approved or authorized by applicable law and regulation in a particular country, territory, or jurisdiction. To learn which products are approved or authorized in particular countries, please consult the appropriate
country-specific website.
Bleeding disorders, also called coagulopathies, occur when
coagulation (blood clotting) is defective. Excessive and prolonged bleeding can occur if a particular component of coagulation is deficient or dysfunctional. Such bleeding can vary in severity and duration and can cause symptoms that range from nosebleeds, bleeding gums, bruising, heavy menstruation, blood in the stool or urine to bleeding into joints causing arthritic-type symptoms, loss of vision and chronic anemia.
1 Bleeding disorders are broadly classified as
congenital (inherited) or
acquired:
- Congenital bleeding disorders are caused by defects or damage in a developing fetus. Congenital defects can be due to inherited abnormalities in genes or chromosomes or to intrauterine conditions, such as infections.2
- Acquired bleeding disorders are those that develop or spontaneously occur in the individual. 3
Over a century ago, CSL Behring began
its enduring journey to save lives and improve the quality of life for people with bleeding disorders. This journey began in 1901, when
Emil von Behring won the first Nobel Prize in Physiology and Medicine for his work on serum therapies.
In 1954, CSL Behring produced the world's first pasteurized plasma protein solution. In doing so, CSL Behring became the first company in the world to fractionate plasma proteins from human plasma in quantities large enough to make them widely available for the treatment of bleeding disorders. In 1981, we marketed the world's first pasteurized factor VIII therapy to treat patients with hemophilia A.
Today, CSL Behring, a member of the CSL Limited group of companies, is a world leader in developing and manufacturing safe and effective therapies to treat and manage a wide range of bleeding disorders such as
Von Willebrand Disease ,
hemophilia A and
B,
fibrinogen deficiency, and other rare and serious factor deficiencies.
CSL Behring is currently developing recombinant factor therapies designed to enable hemophilia patients to go longer between transfusions of factor. This feature, called "extended half-life," is based on proprietary technology that uses recombinant albumin to extend the product’s effectiveness in the body, meaning fewer infusions of product are required.
These therapies, and others in the CSL portfolio, have the potential to offer patients and caregivers a great deal of convenience. CSL's substantial investments in state-of-the-art facilities for production of recombinant fusion albumin proteins in Broadmeadows (Australia), Parkville (Australia) and Marburg (Germany) further demonstrate our commitment to the world’s patient community.
Learn More
References
1. Ma A. Evaluation of the bleeding patient. In: Key N, Makris M, O'Shaughnessy D, Lillicrap D, editors. Practical Hemostasis and Thrombosis. 2nd ed: Wiley-Blackwell, 2009:48–60.2. Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006;4(10):2115-29.
3. Peyvandi F, Palla R. Fibrinogen concentrates. Clin Adv Hematol Oncol 2009;7(12):788-90.
4. CSL Behring. Bleeding Disorders. About Our Therapies., 2011.